Belatacept (BMS 224818) 是一种选择性 T 细胞共刺激 (T-cell costimulation) 阻滞剂。Belatacept 与 CD 80/86 配体结合而抑制 CD-28 介导的 T 细胞共刺激。Belatacept 可用于器官移植免疫抑制的研究。

Belatacept (BMS 224818) is a selective T-cell costimulation blocker. Belatacept binds to CD 80/86 ligands and thereby inhibits the CD-28-mediated T-cell costimulation. Belatacept can be used in the research of Immunosuppression in organ transplants.

Solid

CD80/86

Belatacept (0-5 mg/mL, 1 h) inhibits T-cell proliferation in a dose-dependent manner.
Belatacept (500 ng/mL, 7 days) enhances predominance of effector-memory T-cells after allogeneic stimulation.
Belatacept (100, 500 ng/mL, 7 days) has no effect on differentiation and allogeneic IFNγ production of isolated effector-memory T cells.
Belatacept (10?μg/mL, 1 h) does not inhibit follicular T Cell-dependent B-Cell differentiation.
Belatacept (40?μg/mL, 10 days) reduces plasmablast differentiation, Ig production, and the major transcription factor Blimp-1 in a T cell-independent manner.
Belatacept (40?μg/mL, 30 min) induces activation of the STAT3 transcription factor in stimulated B cells and reduced the expression of CD86.
has not independently confirmed the accuracy of these methods.

Belatacept (intraperitoneal injection, 60 mg/kg) inhibits ABMR (Antibody-Mediated Rejection), and inhibits acute rejection when combined with BTLA (B and T lymphocyte attenuator) overexpression therapy.
Belatacept (intravenous injection, 20 mg/kg) displays immunosuppressive activities in monkeys immunized with sheep red blood cell.
has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Store at 4°C, do not freeze

[1]. George Melvin, et al. Belatacept: A worthy alternative to cyclosporine?. J Pharmacol Pharmacother. 2012 Jan-Mar; 3(1): 90–92.
[2]. Gretchen N de Graav, et al. Down-Regulation of Surface CD28 under Belatacept Treatment: An Escape Mechanism for Antigen-Reactive T-Cells. PLoS One. 2016 Feb 26;11(2):e0148604.